Sultopride

44 interactions 4 explained in plain English

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Lenvatinib Sertraline Dofetilide Goserelin Implant Oxaliplatin Injection Arsenic Trioxide

44 Major

All (44) Major (44)

Major

Sultopride Amitriptyline Elavil Explained An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Sultopride Sertraline Explained An increased risk of QT interval prolongation Details Sultopride Buprenorphine Belbuca Explained An increased risk of QT interval prolongation Details Sultopride Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Sultopride Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Sultopride Arsenic Trioxide Trisenox Prolongation of the QTc interval and/or torsades de pointes Details Sultopride Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Sultopride Arsenic Trioxide Injection Trisenox Prolongation of the QTc interval and/or torsades de pointes Details Sultopride Asenapine Transdermal Patch Secuado Increased risk of QT interval prolongation Details Sultopride Azithromycin AzaSite An increased risk of QT interval prolongation and torsade de pointes Details Sultopride Cabergoline Dostinex® Reduced efficacy of cabergoline and reduced efficacy of dopamine-2 receptors Details Sultopride Bedaquiline Sirturo Increased risk of QT interval prolongation Details Sultopride Chloroquine Aralen® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Sultopride Dasatinib Phyrago An increased risk of QT interval prolongation Details Sultopride Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Sultopride Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Sultopride Disopyramide Norpace An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Sultopride Dofetilide Tikosyn An increased risk of QT interval prolongation, and an increased risk of torsades de pointes Details Sultopride Dolasetron Anzemet An increased risk of cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest) Details Sultopride Dolasetron Injection Anzemet An increased risk of cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest) Details Sultopride Encorafenib Braftovi Increased risk of QT interval prolongation Details Sultopride Entrectinib Rozlytrek An increased risk of QT interval prolongation Details Sultopride Flecainide Tambocor® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Sultopride Foscarnet Injection Foscavir An increased risk of cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest) Details Sultopride Fostemsavir Rukobia Increased risk of torsade de pointes Details Sultopride Gemifloxacin Factive An increased risk of cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest) Details Sultopride Glasdegib Daurismo Increased risk of QT interval prolongation Details Sultopride Goserelin Implant Zoladex Increased risk of QT interval prolongation Details Sultopride Histrelin Implant Supprelin Increased risk of QT interval prolongation Details Sultopride Hydroxychloroquine Plaquenil Increased risk of QT interval prolongation Details Sultopride Inotuzumab Ozogamicin Injection Besponsa Increased risk of QT interval prolongation Details Sultopride Ketoconazole Topical Extina® Foam Increased risk of QT interval prolongation Details Sultopride Lefamulin Xenleta Increased risk of QT interval prolongation Details Sultopride Lenvatinib Lenvima Increased risk of QT-interval prolongation Details Sultopride Loperamide Diamode An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Sultopride Mefloquine Lariam® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Sultopride Metronidazole Flagyl An increased risk of QT interval prolongation Details Sultopride Metronidazole Injection Flagyl An increased risk of QT interval prolongation Details Sultopride Metronidazole Topical MetroCream® An increased risk of QT interval prolongation Details Sultopride Metronidazole Vaginal MetroGel® Vaginal An increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.